Medication continuity among medicaid beneficiaries with schizophrenia and bipolar disorder

Psychiatric Services

Volumn 64, Issue 9, 2013, Pages 878-885

  Brown, Jonathan D ^a   Barrett, Allison ^a   Caffery, Emily ^a   Hourihan, Kerianne ^a   Ireys, Henry T ^a  

^a MATHEMATICA POLICY RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; VALPROIC ACID;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PATIENT CARE; RACE DIFFERENCE; SCHIZOPHRENIA; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; BIPOLAR DISORDER; CONTINUITY OF PATIENT CARE; FEMALE; HUMANS; MALE; MEDICAID; MIDDLE AGED; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 84885401625     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201200349     Document Type: Article

References (29)

1. Kreyenbuhl J, Buchanan RW, Dickerson FB, et al: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophrenia Bulletin 36: 94-103, 2010
2. Grunze H, Vieta E, Goodwin GM, et al: The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World Journal of Biological Psychiatry 11: 81-109, 2010
3. Yatham LN, Kennedy SH, Schaffer A, et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders 11: 225-255, 2009
4. Valenstein M, Blow FC, Copeland LA, et al: Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bulletin 30: 255-264, 2004
5. Gilmer TP, Dolder CR, Lacro JP, et al: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161: 692-699, 2004
6. Lang K, Meyers JL, Korn JR, et al: Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatric Services 61: 1239-1247, 2010
7. Menzin J, Boulanger L, Friedman M, et al: Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatric Services 54: 719-723, 2003
8. Weiden PJ, Kozma C, Grogg A, et al: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services 55: 886-891, 2004
9. Marcus SC, Olfson M: Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophrenia Bulletin 34: 173-180, 2008
10. Hassan M, Lage MJ: Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. American Journal of Health-System Pharmacy 66: 358-365, 2009
11. Olfson M, Mechanic D, Hansell S, et al: Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatric Services 51: 216-222, 2000
12. Dibonaventura M, Gabriel S, Dupclay L, et al: A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 12: 20, 2012
13. Gaudiano BA, Miller IW: Patients' expectancies, the alliance in pharmacotherapy, and treatment outcomes in bipolar disorder. Journal of Consulting and Clinical Psychology 74: 671-676, 2006
14. Fenton WS, Blyler CR, Heinssen RK: Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin 23: 637-651, 1997
15. Hartung DM, Carlson MJ, Kraemer DF, et al: Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population. Medical Care 46: 565-572, 2008
16. Kim E, Gupta S, Bolge S, et al: Adherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional survey. Journal of Medical Economics 13: 185-192, 2010
17. Vogt WB, Joyce G, Xia J, et al: Medicaid cost control measures aimed at secondgeneration antipsychotics led to less use of all antipsychotics. Health Affairs 30: 2346-2354, 2011
18. Soumerai SB, Zhang F, Ross-Degnan D, et al: Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Affairs 27: w185-w195, 2008
19. Lu CY, Soumerai SB, Ross-Degnan D, et al: Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Medical Care 48: 4-9, 2010
20. Soumerai SB, McLaughlin TJ, Ross- Degnan D, et al: Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine 331: 650-655, 1994
21. Farley JF: Medicaid prescription cost containment and schizophrenia: a retrospective examination. Medical Care 48: 440-447, 2010
22. Brown, JD, Barrett A, Ireys H, et al: Evidence-Based Practices for Medicaid Beneficiaries With Schizophrenia and Bipolar Disorder. Washington, DC, Mathematica Policy Research, April 2012. Available at aspe. hhs.gov/daltcp/ reports/2012/ebpsbd.shtml
23. Simon GE, Unützer J: Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatric Services 50: 1303-1308, 1999
24. Unützer J, Simon G, Pabiniak C, et al: The treated prevalence of bipolar disorder in a large staff-model HMO. Psychiatric Services 49: 1072-1078, 1998
25. Pharmaceutical Benefits Under State Medical Assistance Programs. Reston, Va, National Pharmaceutical Council, 2007
26. Bureau of Health Professions, Office of Workforce Policy and Performance Management: User Documentation for the Area Resource File (ARF) 2007 Release. Rockville, Md, US Department of Health and Human Services, Health Resources and Services Administration, 2008
27. Lutterman T, Berhane A, Phelan B, et al: Funding and Characteristics of State Mental Health Agencies, 2007. HHS pub no SMA 09-4424. Rockville, Md, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, 2009
28. Nielsen J, Skadhede S, Correll CU: Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 35: 1997-2004, 2010
29. Robertson TA, Cooke CE, Wang J, et al: Effect of medication burden on persistent use of lipid-lowering drugs among patients with hypertension. American Journal of Managed Care 14: 710-716, 2008